295 related articles for article (PubMed ID: 11300493)
1. Systemic and local immunosuppression in pancreatic cancer patients.
von Bernstorff W; Voss M; Freichel S; Schmid A; Vogel I; Jöhnk C; Henne-Bruns D; Kremer B; Kalthoff H
Clin Cancer Res; 2001 Mar; 7(3 Suppl):925s-932s. PubMed ID: 11300493
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
3. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib up-regulates the expression of the zeta chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer.
Ferrandina G; Ranelletti FO; Legge F; Salutari V; Martinelli E; Fattorossi A; Lorusso D; Zannoni G; Vellone V; Paglia A; Scambia G
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2055-60. PubMed ID: 16609015
[TBL] [Abstract][Full Text] [Related]
6. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma.
Reichert TE; Scheuer C; Day R; Wagner W; Whiteside TL
Cancer; 2001 Jun; 91(11):2136-47. PubMed ID: 11391595
[TBL] [Abstract][Full Text] [Related]
7. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions.
Sikora JJ; Dworacki GT; Kaczmarek MT; Jenek RE; Zeromski JO
Cancer Detect Prev; 2004; 28(5):325-30. PubMed ID: 15542255
[TBL] [Abstract][Full Text] [Related]
9. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
10. Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment.
Zhou Q; Zhu XQ; Zhang J; Xu ZL; Lu P; Wu F
Ultrasound Med Biol; 2008 Jan; 34(1):81-7. PubMed ID: 17854983
[TBL] [Abstract][Full Text] [Related]
11. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.
Schmitz-Winnenthal FH; Volk C; Z'graggen K; Galindo L; Nummer D; Ziouta Y; Bucur M; Weitz J; Schirrmacher V; Büchler MW; Beckhove P
Cancer Res; 2005 Nov; 65(21):10079-87. PubMed ID: 16267034
[TBL] [Abstract][Full Text] [Related]
12. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
13. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
14. Diverse responses between human pancreatic cancer cell lines to native alpha 1-antitrypsin and its C-terminal fragment.
Zelvyte I; Ohlsson B; Axelson J; Janciauskiene S
Anticancer Res; 2003; 23(3B):2267-73. PubMed ID: 12894502
[TBL] [Abstract][Full Text] [Related]
15. The pathogenesis of nasal polyposis by immunoglobulin E and interleukin-5 is completed by transforming growth factor-beta1.
Hirschberg A; Jókúti A; Darvas Z; Almay K; Répássy G; Falus A
Laryngoscope; 2003 Jan; 113(1):120-4. PubMed ID: 12514394
[TBL] [Abstract][Full Text] [Related]
16. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma.
Dworacki G; Meidenbauer N; Kuss I; Hoffmann TK; Gooding W; Lotze M; Whiteside TL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):947s-957s. PubMed ID: 11300496
[TBL] [Abstract][Full Text] [Related]
17. Signal of proteinase-activated receptor-2 contributes to highly malignant potential of human pancreatic cancer by up-regulation of interleukin-8 release.
Ikeda O; Egami H; Ishiko T; Ishikawa S; Kamohara H; Hidaka H; Takahashi M; Ogawa M
Int J Oncol; 2006 Apr; 28(4):939-46. PubMed ID: 16525644
[TBL] [Abstract][Full Text] [Related]
18. Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1.
Ottaviano AJ; Sun L; Ananthanarayanan V; Munshi HG
Cancer Res; 2006 Jul; 66(14):7032-40. PubMed ID: 16849548
[TBL] [Abstract][Full Text] [Related]
19. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
20. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
